Cymabay Therapeutics Overview

Cymabay Therapeutics Selling, General & Admin

Selling, General & Admin expenses for CBAY.

Quarterly SG&A Expenses

$19.81M

↑ 173.3% YoY

As of Dec 31, 2023

Annual SG&A Expenses (TTM)

$51.95M

↑ 106.85% YoY

Trailing 12 months ending Dec 31, 2023

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin